Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02795429
Title Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

hepatocellular carcinoma

Therapies

Spartalizumab

Capmatinib + Spartalizumab

Age Groups: adult | senior
Covered Countries ITA | FRA | DEU | CAN


No variant requirements are available.